Genetic alterations affecting b-catenin, adenomatous polyposis coli or axin proteins are associated with the pathogenesis of numerous human tumors. All these mutations result in the synthesis of unphosphorylated b-catenin that escapes recognition by the b transducin repeat protein (bTrCP1), the receptor of an ubiquitin. The stabilized b-catenin translocates to the nucleus and activates the transcription of genes crucial for tumorigenesis. Recent evidence implicates mutations and overexpresssion of bTrCP1 in human prostate and colon tumors, respectively, suggesting that deregulated bTrCP1 may be involved in tumorigenesis. To explore this possibility further, we generated transgenic mice that specifically express a dominant-negative mutant of bTrCP1 (DFbTrCP1) or full-length bTrCP1 in intestine, liver and kidney. We found that 46% (16/35) of the transgenic mice that overexpressed the transgenes developed either intestinal adenomas (10/35) or hepatic (4/35) or urothelial (2/35) tumors. Immunohistological analysis of the tumors revealed that upregulation of cyclin D1, glutamine synthetase and chemotaxin 2 was associated with nuclear accumulation of b-catenin. These results show that the overexpression of DFbTrCP1 or bTrCP1 in vivo induce tumors through b-catenin activation.
The accumulation of b-catenin is associated with a wide variety of human malignancies including colorectal and hepatic tumors (Polakis, 2000) . In the absence of Wnt signaling, cytoplasmic b-catenin is constitutively phosphorylated by a multiprotein complex including glycogen synthetase kinase-3 (GSK3), the adenomatous polyposis coli (APC) and axin. Phosphorylated b-catenin is recognized by the F-box protein bTrCP1, a component of the SCF (Skp1-Cullin1-F box protein) E3 ubiquitin ligase enzyme and is quickly destroyed through the proteasome pathway. When cells are exposed to Wnt or aberrant activation of Wnt signaling caused by mutations in the b-catenin, APC or axin genes, b-catenin phosphorylation and its subsequent ubiquitination are inhibited. b-Catenin excluded from the proteasome machinery accumulates and enters the nucleus where it binds to transcription factors of the lymphoid enhancer factor/T-cell factor (LEF/TCF) family and activates the expression of c-myc, cyclin D1 and other oncogenes.
Mutations or overexpression of bTrCP1 have been found in human prostate or colon tumors, respectively, implicating bTrCP1 in tumorigenesis (Spiegelman et al., 2000; Gerstein et al., 2002) . Recently, bTrCP1 knockout (KO) mice have been studied but tumorigenesis was rare or absent (Guardavaccaro et al., 2003; Nakayama et al., 2003) . This was probably due to the presence of bTrCP2, the closest homologue of bTrCP1, which also plays a role in degrading b-catenin.
To analyse the involvement of bTrCP1 in carcinogenesis, we constructed transgenic mice expressing DFbTrCP1, a dominant-negative mutant of bTrCP1 (Margottin et al., 1998) . This mutant acts as a negative transdominant by sequestering b-catenin and inhibiting its ubiquitination and degradation by proteasomes even in the presence of bTrCP2 expression (Hart et al., 1999; Kitagawa et al., 1999; Latres et al., 1999) . Overexpressed wild-type bTrCP1 can also act as a dominant negative of the SCF complex and causes b-catenin stabilization instead of degradation (Sadot et al., 2000) . In the current study, we show that the overexpression of DFbTrCP1 or bTrCP1 in mice results in the accumulation of b-catenin and tumorigenesis. We obtained constructs in which the bTrCP1 or DFbTrCP1 cDNA was under the control of the rat calbindin D9 K promoter and the aldolase B enhancer (Figure 1a ) (Romagnolo et al., 1999) and generated mice expressing bTrCP1 or DFbTrCP1. Expression from this promoter is principally in the liver, the intestine and the pelvicalyceal system of the kidney (S Colnot and C Perret, personal communication). Mice of one bTrCP1 transgenic line (A40) and three DFbTrCP1 transgenic lines (B46, B44, B42) were analysed. Total RNAs were isolated from part of the duodenum, the liver and the kidney and studied by Northern blotting (Figure 1b) .
The transgenic line A40 showed high levels of bTrCP1 transcripts in the duodenum, liver and kidney. Two of the three DFbTrCP1 transgenic lines had abundant DFbTrCP1 mRNA in intestine, liver and kidney (B46 and B44) and one had high levels of DFbTrCP1 transcripts only in the kidney (B42) (Figure 1b ). Western blotting with anti-bTrCP antibody was used to probe for DFbTrCP1 and bTrCP1 proteins in tissues in which the transgenes were transcribed (Figure 1c) .
Histological analysis of intestinal sections revealed adenomas of the duodenum in 10/35 (29%) mice that overexpressed bTrCP1 (A40) or DFbTrCP1 (B44 and B46) ( Table 1) . We detected pedunculated duodenal adenoma of low grade in six of 13 (46%) transgenic mice of the A40 line (Figure 2a, b) . In the B44 line, 2/9 (22%) animals had low-grade pedunculated duodenal adenoma, and no intestinal adenoma was found in the B46 line (0/11). To increase the probability of tumor development in the B46 transgenic line, we intercrossed heterozygous B46 mice and obtained two homozygous DFbTrCP1 þ / þ animals as determined by descendent analysis. Histological analysis of these B46 mice revealed high-grade pedunculated adenoma of the duodenum (Figure 2e, f) . No duodenal adenoma were observed among the 15 transgenic mice of the B42 line that do not express the transgene in intestine and the 13 nontransgenic littermates (Table 1) . Thus, overexpression of bTrCP1 or DFbTrCP1 may favor proliferation of epithelial cells in the duodenum and induces tumorigenesis. To determine whether overexpression of bTrCP1 or DFbTrCP1 results in translocation of b-catenin to the nucleus, we investigated the distribution of endogenous b-catenin by immunohistochemistry with an anti-mouse b-catenin antibody. In low-grade duodenal adenomas of A40 line, b-catenin was mainly located on the inner face of the cell membranes but we also observed a focal distribution of cytosolic and nuclear b-catenin ( Figure 2c ). The nuclear b-catenin staining was more diffuse and evenly distributed in high-grade duodenal adenomas detected in the homozygous B46 line (Figure 2g , arrow). We performed immunohistochemical staining with antibodies against cyclin D1 to test for nuclear b-catenin activity in the intestinal adenomas. We observed a strong staining with the anti-cyclin D1 antibody in the nuclei of cells of the intestinal adenomas that show a delocalization of b-catenin. The number of cyclin D1-positive nuclei was greater in the B46 line than in the A40 line ( Figure  2d and h). These data confirm the upregulation of bcatenin in the intestinal tumors and suggest a correlation between nuclear b-catenin or cyclin D1 expression and the grade of the tumor.
Two urothelial papillomas (in line B44 and B46) and one invasive urothelial carcinoma (in line B42) were detected by histological examination of kidneys (Table 1) . The papillomas and the carcinoma were in the pelvicalyceal system of the kidney where the transgenes were overexpressed (data not shown).
Histological analysis of 12 livers from the heterozygous B46 line identified four hepatic tumors (Table 1) . Two were hepatocellular adenomas with one or two (Kroll et al., 1999) were inserted into the EcoRV site of the EAB-GHB-KS polyA vector. This plasmid contains a fragment carrying the promoter, the first exon and intron and the begining of the second exon (before the ATG initiation codon) of the rat calbindin D9 K (CaPB9 K) and the aldolase B enhancer at the 5 0 end of the CaBPK promoter to increase expression of the transgene (Romagnolo et al., 1999) . The resulting constructs, named EAB-GHB-KS-PolyA-DFbTrCP1 and EAB-GHB-KS-PolyA-bTrCP1, allow expression of the transgenes in the pelvicalyceal system of kidney, the intestine and the liver. The interactions between bTrCP or its mutant DFbTrCP and b-catenin and Skp 1 are summarized (indicated by plus and minus signs). These constructs were microinjected into fertilized B6D2 mouse eggs (C57Black6-Â DBA). Eggs were retransplanted into B6CBA pseudogestants (C57Black6 Â CBA) mice. Transgenic mice were identified by Southern blotting, using tail DNA digested with BamHI and a P32-labeled human bTrCP1 cDNA probe. (b) Northern blot analysis of representative transgenic lines expressing bTrCP1 or DFbTrCP1. Total RNA were extracted from frozen samples of mouse bTrCP1 (named A), DFbTrCP1 (named B) transgenic or nontransgenic (NT) livers, kidneys or duodena and were analysed by Northern blotting. Amounts of 20 mg aliquots of RNA were electrophoresed through 1.3% agarose-6% formaldehyde gels. The names of the transgenic lines are indicated above the blot. Upper panel: The RNAs were transferred to Hybond N þ membranes and hybridized with a 32 P-labeled bTrCP1 cDNA probe. Lower panel:
The loading control shows 18S RNA stained by methylene blue on the membrane. (c) bTrCP1 or DFbTrCP1 proteins in transgenic mice. Western blot analysis of liver samples obtained from heterozygous B46 and A40 transgenic lines and nontransgenic mice was prepared as described previously (Cadoret et al., 2002) . DFbTrCP1 or bTrCP1 proteins were detected using anti-bTrCP goat polyclonal antibody (C18, Tebu laboratories) DFbTrCP1 transgenic expression induces tumors N Belaïdouni et al Figure 2 Histological and immunohistochemical analysis of paraffin-embedded sections of duodenum showing adenoma in the bTrCP1 and DFbTrCP1 transgenic mice. Formalin-fixed paraffin-embedded sections from duodenum were hematoxylin and eosin (HE) stained as described previously (Romagnolo et al., 1999; Cadoret et al., 2002) . The sections were immunostained with antib-catenin (1/500 dilution, Transduction laboratories) and anti-cyclin D1 (DCS-6 1/30 or 1/50 dilution, Dako) mouse monoclonal antibodies as previously described (Romagnolo et al., 1999) . DFbTrCP1 transgenic expression induces tumors N Belaïdouni et al distinct nodules of 2-5 mm diameter located at the surface of the liver and two were very large hepatocellular carcinomas (HCC). The HCCs had abnormal tissue architecture with no portal tract, considerable cellular heterogeneity, and major cytonuclear anomalies (Figure 3a) . b-Catenin was found in both cytosol and nucleus in HCC cells (Figure 3b ). Upregulation of cyclin D1 was observed in the nuclei of HCC cells (Figure 3c ). We also tested for the expression of glutamine synthetase (GS) and chemotaxin 2 (LECT2), two other target genes of b-catenin which are induced in the liver (Cadoret et al., 2002; Ovejero et al., 2004) . In normal liver tissues, GS and LECT2 staining were restricted to a small population of hepatocytes around the central veins (Figure 3e and g ). In contrast, hepatic tumor tissue from the transgenic B46 line was uniformly stained for GS and LECT2 (Figure 3f and h ). This result suggests that activation of b-catenin in the HCCs is associated with overexpression of GS and LECT2. Previously, we showed that the inhibition of bTrCP1 may promote the accumulation of IkBa, another substrate of bTrCP1 and bTrCP2, and leads to the sequestration of NFkB by IkBa in the cytoplasm (Besnard-Gue´rin et al., 2004) . By immunochemistry, using an antibody against the p65 subunit of NFkB, we found that NFkB expression is increased in the cytoplasm of the HCC tissues compared with normal tissues surrounding the tumor ( Figure 3i) ; however, no nuclear translocation of NFkB is detected in this tumor (Figure 3j ). This result suggests that NFkB may not be activated as a result of the inhibition of IkBa degradation by DFbTrCP1 proteins (see also Supplementary Figure A) . Here, we present data for mouse transgenic lines that specifically expressed either bTrCP1 or DFbTrCP1 in the intestine, the liver and in the pelvicalyceal system of the kidney. In total, 46% of the animals of the transgenic line that overexpresses bTrCP1 had adenomas in the duodenum. For the two transgenic lines that overexpress DFbTrCP in the three tissues, 33 and 54% of animals developed tumors including duodenal adenomas, urothelial papillomas and hepatic tumors. These tumors were associated with an increase in cell proliferation revealed by Ki67 staining (data not shown). b-Catenin was translocated to the nucleus in tumor cells suggesting that it is involved in the tumorigenesis induced by overexpression of bTrCP1 or DFbTrCP1. In accordance, we detected expression of Glutamine synthetase staining using a monoclonal mouse antibody (Transduction laboratories, 1/200 dilution) as previously described (Cadoret et al., 2002) shows perivenous aeras in normal liver cells (G Â 25). (f) The GS staining is homogeneous in the HCC tumor (T), whereas the adjacent nontumoral tissue (N) without perivenous aeras reveals no staining (G Â 100). (g) LECT2 staining using a mouse antibody as previously described (Ovejero et al., 2004) reveals expression only to the perivenous region in normal liver cells as for GS staining (G Â 25). cyclin D1 in the duodenal tumors. The observation that expression of the glutamine synthetase and chemotaxin 2 were induced in the liver tumors confirmed that an activation of the b-catenin signaling was involved in the process of tumor formation induced by overexpression of the bTrCP1 or DFbTrCP1. The stabilization of b-catenin in tumors generated by transgenic expression of bTrCP1 is likely due to the sequestration of a limited amount of Skp1 or other SCF components by overexpressed bTrCP1. Thus, upregulation of b-catenin expression by six-fold and 11.5-fold has been previously detected, respectively, in bTrCP1 or DFbTrCP1 transfected cells (Sadot et al., 2000) . bTrCP1 binds b-catenin via the WD40-repeat domain and Skp1 via the F-box domain. It is possible that some bTrCP1 proteins linked to b-catenin but not associated with Skp1 are unable to induce degradation of b-catenin as the DFbTrCP1 mutated proteins. To test this hypothesis, we transfected HeLa cells with increasing amounts of bTrCP1 plasmids and coimmunoprecipitated b-catenin associated with bTrCP using an anti-bTrCP antibody (see also Supplementary Figure B) . By Western blot, we observed an increased amount of endogenous b-catenin coimmunoprecipitated concomitant with the increasing amount of transfected bTrCP1. In contrast, the detection of the endogenous Skp1 coimmunoprecipitated with bTrCP revealed equivalent amounts. These results suggest that no more Skp1 molecules were available to link to the bTrCP1 proteins expressed in the transfected cells. These data could explain why b-catenin could be upregulated instead of downregulated when the bTrCP1 gene is overexpressed (data not shown).
It is interesting to note that nuclear b-catenin accumulation was more frequently observed in highgrade than in low-grade duodenal tumors. These data suggest that the early lesions obtained after overexpression of bTrCP1 or DFbTrCP1 in intestine do not require a strong deregulation of b-catenin but predispose to the development of high-grade dysplasia associated with high dysregulated b-catenin signaling. In conclusion, by using a transgenic approach, we show that the overexpression in vivo of the transdominant negative DFbTrCP1 or bTrCP1 might contribute to oncogenesis in mice through b-catenin activation.
Previously, overexpression or mutations of bTrCP1 have been detected in human tumors. bTrCP1 overexpression was found in five of seven primary human colorectal carcinomas tested and was associated with elevated b-catenin levels (Spiegelman et al., 2000) . More recently, a study of 22 human prostate tumors revealed deletions in bTrCP1 transcripts in two samples (a prostate tumoral cell line and a human prostate tumor transplanted into mice) suggesting b-catenin upregulation in these human tumoral cells. Three other xenografts showed alterations in the APC gene and two primary tumors contained mutations in the bcatenin gene. All these mutations were mutually exclusive. This was the first evidence of bTrCP1 alterations in human tumors (Gerstein et al., 2002) . The role of bTrCP1 in controlling proliferation has also been studied using KO cell lines lacking bTrCP1.
Embryonic fibroblasts derived from bTrCP1 KO mice have defects in cell division (Guardavaccaro et al., 2003) likely due to Emi1 stabilization . bTrCP1 KO mice suffered a very small number of tumors (one invasive adenocarcinoma of the intestine and two thymic lymphomas among 50 bTrCP1À/À mice) or no tumors (Guardavaccaro et al., 2003; Nakayama et al., 2003) . This finding could be explained by the fact that bTrCP2, very similar to bTrCP1, is expressed in bTrCP1 KO mice and can induce the degradation of b-catenin preventing its accumulation. Indeed, little or no increase in b-catenin levels were reported in bTrCP1À/À embryonic fibroblasts (Guardavaccaro et al., 2003; Nakayama et al., 2003) . Consistent with this hypothesis, the transfection in HeLa cells of siRNA oligos reducing the expression of both bTrCP1 and bTrCP2 leads to the stabilization and accumulation of b-catenin, whereas the transfection of siRNA oligos specific of bTrCP1 or bTrCP2 transcripts causes the degradation of b-catenin (Guardavaccaro et al., 2003) . In contrast, the DFbTrCP1 or bTrCP1 proteins in transgenic mice can interfere with the substrates of both bTrCP1 and bTrCP2 and thereby stabilize b-catenin.
Further support that the b-catenin proteins express in these transgenic mice are functional and involved in tumorigenesis comes from previous studies showing that presence of mutant b-catenin into mice results in enhanced tumor formation. Transgenic mice bearing a mutated b-catenin gene develop adenoma, dysplasic lesions and polyps in the small intestine (Harada et al., 1999; Romagnolo et al., 1999) . Thus, neoplasia detected in the small intestine of the DFbTrCP1 or bTrCP1 transgenic mice is a recognized feature to the phenotype detected in these mice expressing a mutated b-catenin. The b-catenin gene is frequently mutated in HCC (De La Coste et al., 1998) ; however, no neoplasia was found in the liver of transgenic mice expressing a mutated b-catenin that presented hepatomegaly quickly after birth and died (Cadoret et al., 2001; Harada et al., 2002) . HCC could take several months to develop as observed in DFbTrCP1 transgenic mice and b-catenin activation may not be sufficient to induce tumorigenesis. bTrCP1 and/or bTrCP2 are known to bind b-catenin and IkBa, but also other substrates such as ATF4 and Emi1 and it is likely that the bTrCP1 disruption leads to the stabilization of numerous substrates (Fuchs et al., 2004) . We show that the NFkB pathway is not activated but additional investigations will be needed to explore whether other signaling pathways are activated and may contribute to tumorigenesis.
In summary, the present results provide for the first time, in a mouse model, evidence that bTrCP1 can be involved in a tumorigenesis pathway resulting in b-catenin accumulation, and activation of several genes, including cyclin D1, glutamine synthetase and chemotaxin 2, that are downstream targets of b-catenin.
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